[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573331":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":27,"studyPopulation":20,"armGroups":28,"interventions":35,"overallOfficials":41,"centralContacts":45,"locations":20,"responsibleParty":52,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":20,"overallStatus":71,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":20},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"PFS","PFS was defined as the time from study entry until disease progression","2 years",[14,17],{"measure":15,"description":16,"timeFrame":12},"EFS","EFS was defined as the time from treatment initiation to progression, relapse, new treatment, or death by any cause, whichever occurred first.",{"measure":18,"description":19,"timeFrame":12},"OS","OS was defined as the time from treatment initiation to death by any cause.",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NA","SINGLE_GROUP","TREATMENT",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE","The investigators will evaluate safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma post complete remission. Event-free survival (EFS), progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.",[29],{"label":30,"type":31,"description":32,"interventionNames":33},"Maintenance Therapy","EXPERIMENTAL","Patients were treated by Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy",[34],"Drug: Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":20},"DRUG","Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy","Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.",[30],[42],{"name":43,"affiliation":5,"role":44},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[46,50],{"name":43,"role":47,"phone":48,"phoneExt":20,"email":49},"CONTACT","+861066947194","qlr2007@126.com",{"name":51,"role":47,"phone":20,"phoneExt":20,"email":20},"Liren Qian",{"type":44,"investigatorFullName":51,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Associate Chief Physician, Associate Professor","100573331",false,"NCT06744894","SIL as Maintenance Therapy in Multiple Myeloma","Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma","Inclusion Criteria:\n\n* Pathologically confirmed Multiple Myeloma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Documented response to ASCT (PR, VGPR, CR\u002Fstringent complete response \\[sCR\\]) according to IMWG criteria.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":63,"type":64},50,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.",[70],"Multiple Myeloma","NOT_YET_RECRUITING","2024-12-17",{"date":74,"type":75},"2024-12-20","ACTUAL",{"date":77,"type":64},"2025-01-01",{"date":79,"type":64},"2030-01-01",{"name":5,"class":6}]